T A B L E O F C O N T E N

Main results
This review includes eight studies with a total of 250 participants comparing nebuliser versus pMDI plus spacer treatment. We identified no studies comparing DPI with nebulisers. We found two studies assessing the primary outcome of 'change in forced expiratory volume in one second (FEV 1 ) one hour after dosing'. We could not pool these studies, but both showed a non-significant difference in favour of the nebuliser group, with similar frequencies of serious adverse events. For the secondary outcome, 'change in FEV 1 closest to one hour after dosing': we found a significant difference of 83 ml (95% CI 10 to 156, P = 0.03) in favour of nebuliser treatment. For the secondary outcome of adverse events, we found a non-significant odds ratio of 1.65 (95% CI 0.42 to 6.48) in favour of the pMDI plus spacer group.
Authors' conclusions
There is a lack of evidence in favour of one mode of delivery over another for bronchodilators during exacerbations of COPD. We found no difference between nebulisers versus pMDI plus spacer regarding the primary outcomes of FEV 1 at one hour and safety. For the secondary outcome 'change in FEV 1 closest to one hour after dosing' during an exacerbation of COPD, we found a greater improvement in FEV 1 when treating with nebulisers than with pMDI plus spacers.
A limited amount of data are available (eight studies involving 250 participants). These studies were difficult to pool, of low quality and did not provide enough evidence to favour one mode of delivery over another. No data of sufficient quality have been published comparing nebulisers versus DPIs in this setting. More studies are required to assess the optimal mode of delivery during exacerbations of COPD.
P L A I N L A N G U A G E S U M M A R Y
Bronchodilators delivered by nebuliser versus inhalers for lung attacks of chronic obstructive pulmonary disease
Review question
When someone is suffering from a lung attack due to chronic obstructive pulmonary disease (COPD), are inhalers with a spacer as good as nebulisers?
Background
Someone experiencing a lung attack suffers from shortness of breath because the airways are narrowed. Bronchodilators are a type of drug that helps to open these airways, but the best way to deliver them to the body is unknown. We searched for the best delivery device during lung attacks, focusing on whether there is a difference between wet nebulisers, which allow people to breathe in medicine as a mist using a mask or mouthpiece, compared with inhalers.
What evidence did we find?
We found eight studies including 250 participants in a search of the available studies up to 1 July 2016. All of the studies took place in a hospital.
What do the studies tell us?
The primary outcomes of the review showed no difference between the inhaler with a spacer and the nebuliser. However, in our secondary outcomes, we found some evidence that nebuliser treatment improves lung function more than inhalers with a spacer, but the quality and quantity of the data is limited. We found no difference between the therapies in terms of side effects or for reducing breathlessness. There are no studies available testing dry powder inhalation against a nebuliser.
Conclusion
Due to the low quality and quantity of the data, it is not clear whether nebulisers or inhalers with spacers are better for lung attacks. We found no difference between an inhaler with a spacer and the nebuliser in lung function after one hour or in unwanted side effects during lung attacks of COPD. The secondary outcome for lung function did favour nebulisers over inhalers with a spacer.
The m ean change in FEV 1 1 h af ter dosing in the pM DI group was 103 ml
The m ean change in FEV 1 1 h af ter dosing in the nebuliser group was 36 ml more (f rom 38 m l f ewer to 110 m l m ore) 
Change in FEV 1 closest to 1 h after dosing in ml
The m ean change in FEV 1 closest to 1 h after dosing in the pM DI group is93 ml
The m ean change in FEV 1 closest to 1 h af ter dosing in the nebuliser groups was 83 ml more (10 to 156 m l m ore)
Change in dyspnoea score during the first 24 h after dosing
The m ean change in dyspnoea score during the f irst 24 h after dosing−1.28 points on the Borg scale (lower score indicates reduced dyspnoea)
The m ean change in dyspnoea score during the f irst 24 h af ter dosing was 0.12 points worse (0.56 better to 0. 79 worse) on the Borg -74 (2) ⊕⊕ Low b
A lower Borg score indicates reduced dyspnoea
B A C K G R O U N D Description of the condition
Chronic obstructive pulmonary disease (COPD) is one of the most important respiratory diseases and the third leading cause of death worldwide (WHO 2014 
Description of the intervention
Bonchodilation is important in the medical treatment of COPD, both in stable state and during exacerbations (GOLD 2015) . The choice of drug, dose and device all contribute to the success of inhaled medication in their own way, but remarkable differences exist in the prescribing habits of individual clinicians in all of these areas.
The inhaled bronchodilators used in COPD are short-acting beta 2 -agonists (SABA), long-acting beta 2 -agonists (LABA), and short-and long-acting anticholinergics. These are administered through various devices (GOLD 2015) . Many clinicians choose to treat patients with nebulisers, especially in the acute setting, and many patients claim to benefit from them (Zheng 2014). However, evidence supporting this choice from systematic analysis is lacking, and the available data are frequently biased by the inclusion of asthma patients (Greene 1988; Jasper 1987; Mandelberg 1997; Turner 1997) . This Cochrane review will assess the evidence available on nebulised bronchodilator treatment versus delivery by pressurised metered dose inhalers (pMDI) with spacer or by dry powder inhalers (DPI) for acute exacerbations of COPD. We published our planned strategy and methods earlier as a protocol (Van Geffen 2015b).
How the intervention might work
Prior research has clearly established the benefit of bronchodilation in treating patients with COPD. Several systematic reviews have shown this for bronchodilators in a stable state of COPD (Appleton 2006; Kew 2014) . During exacerbations, experts also recommend the use of bronchodilation (GOLD 2015) . Hence, bronchodilators are common in treatment of COPD exacerbations all over the world. However, less is known about the best mode of delivery for these treatments, especially during exacerbations. Important features known to affect the deposition include particle size, choice of the device, respiration pattern and inhalation technique. During exacerbations of COPD, nebulisers, as well as pMDIs and DPIs, have been shown to be useful in delivering medication into the lungs (Demoly 2014; Mazhar 2008) . However, there are differences between device types, which may lead to differences in efficacy. For instance, the use of nebulisers is more time-consuming compared with pMDI/DPI, and patients require a better technique to inhale their bronchodilators by DPI and especially pMDI without spacer. Due to the nature of exacerbations, the best choice of a delivery method for bronchodilators may differ from stable state.
Why it is important to do this review
Although there is consensus on the use of bronchodilators, there has been little attention to the mode of delivery. As a consequence, wide variations in practice exist between and within countries and even among doctors in the same hospital. We assessed the available RCTs to help guide practice in a more uniform way.
O B J E C T I V E S
To compare the effects of nebulisers versus pressurised metered dose inhalers (pMDI) plus spacer or dry powder inhalers (DPI) in bronchodilator therapy for exacerbations of COPD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) of both parallel and cross-over designs.
Types of participants
We included studies in participants with an exacerbation of COPD receiving treatment at home, in the clinic or in hospital. We excluded RCTs involving mechanically ventilated patients due to the different condition of both patients and airways in this setting. We also excluded people with asthma from our analysis.
Types of interventions
We included trials comparing a bronchodilator medication by nebuliser with the same bronchodilator medication by either pMDI (with or without spacer) or DPI. We allowed co-interventions including inhaled steroids. 
Types of outcome measures
Search methods for identification of studies Electronic searches
We identified trials from the Cochrane Airways Group Specialised Register (CAGR), which is maintained by the Information Specialist for the Cochrane Airways Group. The CAGR contains trial reports identified through systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and handsearching of respiratory journals and meeting abstracts (please see Appendix 1 for further details). We searched all records in the CAGR using the search strategy in Appendix 2 up to 1 July 2016. We also searched ClinicalTrials.gov (clinicaltrials.gov) and the World Health Organization (WHO) trials portal (who.int/ictrp/ en/). We searched both databases from their inception 1 July 2016, and we imposed no restriction on language of publication.
Searching other resources
We checked reference lists of all primary trials and review articles for additional references. We searched for errata and retractions from included trials published in full-text on PubMed ( www.ncbi.nlm.nih.gov/pubmed) to 1 July 2016.
Data collection and analysis
Selection of studies
Two review authors (WG and HK) independently screened titles and abstracts for inclusion of all the potential trials identified as a result of the search and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. Based on the consensus reached, we retrieved the full texts for assessment. Two review authors independently screened the full-text records and identified trials for inclusion. We reported the reasons for excluding the ineligible trials in a 'Characteristics of excluded studies' table. We resolved any disagreements through discussion or, if required, we consulted a third review author. We identified and excluded duplicates and collated multiple reports of the same trial so that each trial rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (Figure 1 ).
Data extraction and management
We used a data collection form, which we piloted on one included study, to record trial characteristics and outcome data. Two review authors extracted the following trial characteristics from included trials.
1. Methods: trial design, total duration of trial, details of any 'run-in' period, number of trial centres and location, trial setting, withdrawals and date of trial.
2. Participants: N, mean age, age range, sex, severity of condition, diagnostic criteria, baseline lung function, smoking history, and inclusion and exclusion criteria.
3. Interventions: intervention, comparison, concomitant medications and excluded medications.
4. Outcomes: primary and secondary outcomes specified and collected, and time points reported. 5. Notes: funding for trial and notable conflicts of interest of trial authors. Two review authors extracted outcome data from the included trials. We noted in the 'Characteristics of included studies' table if outcome data was not reported in a usable way. We resolved disagreements by consensus or by involving a third review author. One review author, WG, transferred data into Review Manager (RevMan 2014). We double-checked that data were entered correctly by comparing the data presented in the systematic review with the trial reports. A second review author checked the papers' trial characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors assessed risk of bias for each trial using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We resolved any disagreements by discussion or by involving a third review author. We assessed the risk of bias according to the following domains.
1. Random sequence generation. 2. Allocation concealment. 3. Blinding of participants and personnel. 4. Blinding of outcome assessment. 5. Incomplete outcome data. 6. Selective outcome reporting. 7. Other bias. We graded each potential source of bias as either 'high', 'low', or 'unclear' and provided a quote from the trial report or a justification for our judgment in the 'Risk of bias' table. We summarised the 'Risk of bias' judgements across different trials for each of the domains listed. We considered blinding separately for different key outcomes where necessary (e.g. for unblinded outcome assessment, risk of bias for all-cause mortality may be very different than for a patient-reported pain scale). Where information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' summary ( Figure 2 ). When considering treatment effects, we took into account the risk of bias for the trials that contributed to that outcome.
Assessment of bias in conducting the systematic review
The review was conducted according to the published protocol (Van Geffen 2015b), and we report any deviations from it in the 'Differences between protocol and review' section.
Measures of treatment effect
We analysed dichotomous data as odds ratios (OR) and continuous data as mean difference (MD) or standardised mean difference (SMD). We entered data presented as a scale with a consistent direction of effect. To analyse the cross-over trials included in Analyses 1.1, 2.2 and 2.3, we used the generic inverse variance (GIV) method. We undertook meta-analyses only where it was meaningful to do so, that is, if the treatments, participants, and the underlying clinical question were similar enough for pooling to make sense. We narratively described skewed data reported as medians and interquartile ranges. For these studies, we expected to have to standardise the results of the studies to a uniform scale before combining them. The SMD expresses the size of the intervention effect in each study relative to the variability observed in that study. However, we could not use the SMD due to the cross-over design of some of the included studies. In the studies where this was the case, we decided to present the data as a mean difference only.
Unit of analysis issues
If we had identified both cluster RCTs and individual RCTs, we planned to synthesise the acquired data. We planned to combine the results if we only detected a little heterogeneity between the trial designs, and we considered bias based on the choice of randomisation unit to be unlikely. Otherwise, we would have adjusted the sample sizes or standard errors using the methods described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
Dealing with missing data
When we thought missing data could introduce serious bias, we explored the impact of including such studies in the overall assessment of results by performing a sensitivity analysis. The studies we examined for the primary outcomes mostly had relatively short-term outcomes. We found some missing data for the primary outcomes. In the case of Turner 1988, we managed to obtain original data, and we were able to calculate some of the missing data. We did not impute or extrapolate existing data.
Assessment of heterogeneity
We used the I 2 statistic to assess heterogeneity among the studies in each analysis. Where we identified substantial heterogeneity, we have reported it and explored possible causes.
Assessment of reporting biases
Had we been able to pool more than 10 studies, we would have created and examined funnel plots to explore possible small trial and publication biases. However, we did not reach a pool of 10 studies.
Data synthesis
We used a random-effects model and performed a sensitivity analysis with a fixed-effect model. We used the standard deviations to standardise the mean differences to a single scale and compute trial weights.
Subgroup analysis and investigation of heterogeneity
We planned to analyse data according to bronchodilators used,mechanism (anticholinergic or beta-adrenergic), and shortacting versus long-acting beta 2 -agonists, analysing subgroups separately for SABA, LABA, SAMA, LAMA, and SABA/LAMA combinations. We also planned to analyse the data from single dose trials in the primary outcomes, and to analyse a subgroup of multiple treatment (doses) trials for the primary and secondary outcomes. However, due to the small number of studies included in our review, subgroup analyses (e.g. for dose or device) were underpowered. Therefore, we decided to assess all data pooled.
Sensitivity analysis
We assessed the risk of introducing bias due to missing data through a sensitivity analysis of our primary outcomes by comparing Berry 1989 and Mazhar 2007 with the other studies assessed as being at low risk of bias.
'Summary of findings' table
We created a 'Summary of findings' table using both the primary and secondary outcomes (Summary of findings for the main comparison). We used the five GRADE considerations (trial limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of the body of evidence as it relates to the trials contributing data to the meta-analyses for the prespecified outcomes. We used methods and recommendations described in Section 8.5 and Chapter 12 of Higgins 2011, using GRADEpro software (GRADEpro GDT). We detailed all decisions to downgrade or upgrade the quality of trials in the 'Summary of findings' table footnotes and made comments to aid readers' understanding of the review where necessary.
R E S U L T S Description of studies Results of the search
We found 1082 records from the Cochrane Airways Group Specialised Register. After scanning titles and abstracts, we selected 44 for full-text review. In addition, we identified 277 records from ClinicalTrials.gov (clinicaltrials.gov) and 80 from the WHO trials portal (www.who.int/ictrp/en/). Of these, we selected only one additional ongoing study (NCT02291016), with no available data. We found 12 additional references through other sources. We analysed those 56 articles in detail, as reported in Figure 1 .
Included studies
See the 'Characteristics of included studies' for full details. We identified eight studies with an appropriate design to evaluate our predefined outcomes. A total of 250 participants with COPD were randomised to doses of aerosol with an inhaler plus spacer or a nebuliser treatment. Six out of the eight included studies reported excluding participants experiencing the most severe exacerbations, using criteria such as pH < 7.30 kPa, inability to perform spirometry or stand unsupported, respiratory failure or requiring mechanical ventilation. We identified no studies reporting on dry powder inhaler versus a nebuliser. We included studies with single or multiple dose and cross-over designs. The studies took place in hospital settings in the United States (Berry 1989; Maguire 1991; Moss 1985; Shortall 2002; Turner 1988) , the United Kingdom (Higgins 1987; Mazhar 2007), and Turkey (Mirici 2004) . The studies used different beta 2 -agonists, anticholinergics, pMDIs, spacers and nebulisers. We noticed a difference in dosage ratio between the pMDI/spacer and nebuliser in the studies. This ratio varies from 1:1 in Higgins 1987 to 1:11.5 in Maguire 1991.
Excluded studies
See the 'Characteristics of excluded studies' table for full details. Most commonly, we excluded studies in the ventilation setting, studies without an appropriate comparator to answer our hypothesis and studies mixing results for asthma and COPD.
Risk of bias in included studies
See Figure 2 for the 'Risk of bias' summary. For each study, we describe the 'Risk of bias' assessment in the 'Characteristics of included studies' table. The methodological quality of the studies included varied. Most of the studies did not describe the method of sequence generation, allocation concealment, or blinding of outcome assessment. None of the included studies reported the use of an intention-to-treat analysis or a power analysis. One study did not adequately describe the use of a spacer in their manuscript (Moss 1985) . However, we decided to include Moss 1985 in our analysis based on the following arguments: we estimated that they did use a spacer in their study; according to our protocol, we had agreed to include studies that did not use a spacer; based on the reported trial design, we assessed this study to be of sufficient quality to be included in this analysis; and the study has been included in another meta-analysis (Turner 1997).
Allocation
Only Mirici 2004 and Turner 1988 reported the use of a computer-generated list of random numbers; the other six included studies may have been influenced by selection bias. Mirici 2004 adequately described their allocation blinding, and based on the overall quality of Turner 1988, we deemed the risk for selection bias due to allocation concealment methods to be low.
Blinding
Three studies were not blinded (Maguire 1991; Mazhar 2007; Shortall 2002) , so the risk of performance and detection bias in these studies is high. The other studies were all double-blinded.
Incomplete outcome data
The risk of attrition bias was high in three of the studies using peak expiratory flow (PEF) measurements in the analysis, because FEV 1 measurements after hospitalisation were not available for all participants (Mirici 2004; Moss 1985; Shortall 2002) . Moss 1985 was never published as a full paper. Shortall 2002 reported that 4 participants of the oral/pMDI group and 12 in the intravenous/ nebuliser group did not complete the trial. It remains unclear why these participants dropped out and what caused the imbalance between the groups in the number of drop-outs.
Selective reporting
We observed a risk of selective reporting bias in three studies where authors described a change in FEV 1 in the methods but did not report it (Higgins 1987; Mirici 2004; Moss 1985) . Mirici 2004 did not report FEV 1 and forced vital capacity (FVC) measurements after hospitalisation. The abstract of Moss 1985 was not published as a full paper, leading to a high risk of reporting bias.
Other potential sources of bias
An important issue to consider is a difference in dose ratio between the pMDI/spacer and the nebuliser in the studies. This ratio varies from 1:1 in Higgins 1987 to 1:11.5 in Maguire 1991. 
Effects of interventions
Serious adverse events
There were no significant differences in the occurrence of serious adverse events between the two delivery methods in the two trials that reported on this outcome (Mirici 2004; Turner 1988 There were no data available regarding change in peak FEV 1 .
Change in FEV 1 closest to one hour after dosing
We pooled reported data change in millilitres. According to our protocol, we could include cross-over designs (Van Geffen 2015b) . This resulted in the fact that studies reporting a different scale of data could not be included in the meta-analysis. The forest plot shows a significant difference of 83 ml (95% CI 10 to 156, P = 0.03) in favour of the nebuliser treatment (Figure 4 We were not able to find data about additional time points other than those reported in the analyses above. Therefore, we did not deem a separate analysis to be meaningful for this outcome.
Change in dyspnoea score during the first 24 hours after dosing
Based on data from two studies measuring dyspnoea with Borg's scale, we found no significant change in dyspnoea score (Berry 1989; Shortall 2002) . One additional study also used this scale, reporting no significant difference between the groups (Turner 1988). However, we were not able to obtain the raw data for this outcome to recalculate their numbers to our previously defined outcome. Based on the included data, we found a non-significant difference of 0.12 points (95% CI −0.56 to 0.79; P = 0.73) in favour of the pMDI group ( Figure 5 ). There were no data available about change in quality of life on the first day of dosing.
Admission rates
We found no significant difference in admission rate. Turner 1988 took place at the emergency department, reporting two admissions in both the pMDI and nebuliser group. We nevertheless found a non-significant difference in favour of the nebuliser group (OR: 0.80, 95% CI 0.09 to 7.00) because the nebuliser group contained slightly more participants.
Time in hospital emergency department
Although Turner 1988 was performed at the emergency department, it did not report on time in the emergency department. Thus we could not extract data about this outcome.
Length of hospital stay
We found no significant difference in hospital stay in the one study reporting this outcome: Shortall 2002 reported a non-significant difference in favour of the pMDI group of 0.80 days (95% CI −1.05 to 2.65, P = 0.40).
Mirici 2004 reported a change in oxygen saturation at several time points after inclusion. There were no significant changes at 30 minutes after the first dose or at the other reported time points (6 h, 24 h, 48 h or 10 d).
Hospital readmission in 30 days
There were no data available about hospital readmission rates in 30 days.
Adverse events/side effects
We found no significant differences between the groups concerning adverse events in the three studies reporting on this outcome (Higgins 1987; Mirici 2004; Turner 1988) . Turner 1988 reported two adverse events in the nebuliser group; however, they did not explain the nature of these events. One participant in Higgins 1987 developed a marked fall in saturation from 88% to 73% 15 minutes after taking the nebuliser treatment. As stated earlier in the primary outcome section, Mirici 2004 reported two participants developing a pneumothorax and one participant requiring mechanical ventilation in the nebuliser group, and three participants developing a pneumothorax in the pMDI group (Figure 6 ). 
D I S C U S S I O N Summary of main results
There is a lack of evidence favouring one mode of bronchodilator delivery over another during exacerbations of COPD. We found no difference between nebulisers and pMDI plus spacer regarding the primary outcomes FEV 1 at one hour and safety. The secondary outcome 'change in FEV 1 closest to one hour after dosing' showed a greater improvement in FEV 1 when treating with nebulisers than with pMDI plus spacers. A limited amount of data are available (eight studies involving 250 participants). These studies were difficult to pool. There were no available study data to enable us to include data about DPIs in our analysis.
Bronchusobstruction
The search for better parameters for acute, severe COPD exacerbations is ongoing (Van Geffen 2015a), but for now, FEV 1 continues to be an important parameter in clinical trials for COPD exacerbations. This review assessed change in FEV 1 at several time points. We found no significant differences between the pMDI and nebuliser group for a change in FEV 1 at one hour after dosing, but we could not pool the available data. The secondary outcome, 'change in FEV 1 closest to one hour after dosing', showed a greater improvement in FEV 1 in the nebuliser group than in the pMDI plus spacers group. Overall, there is a lack of evidence favouring one mode of delivery over another for bronchodilators during exacerbations of COPD with regard to bronchus obstruction.
Adverse events
Three studies reported on adverse events (Higgins 1987; Mirici 2004; Turner 1988) . This is the first time the data have been pooled and assessed systematically. Adverse and especially serious adverse events might influence the device choice for physicians when treating patients with COPD exacerbations. However, with current available data in this systematic review, we found no significant differences between pMDI and nebuliser treatment. Overall, there is a lack of evidence favouring one mode of delivery for bronchodilators over another during exacerbations of COPD with regard to adverse events.
Dyspnoea and quality of life
Patient-reported outcomes are becoming more important in current practice. Patient-reported outcomes include scoring of dyspnoea and quality of life. The analysis of dyspnoea showed no significant differences between pMDI and nebuliser treatment. We did not identify any data about quality of life. Overall, there is a lack of evidence favouring one mode of delivery for bronchodilators over another during exacerbations of COPD with regard to dyspnoea and quality of life.
Clinically important outcomes
This systematic review assessed additional clinically important outcomes, used both by physicians and policymakers on a daily basis. We were surprised by the lack of data about admission rates, time in the hospital emergency department, length of hospital stay, and hospital readmission within 30 days. These are perhaps parameters that have only recently become more important, and additionally necessitate longer trials. Overall. there is a lack of evidence favouring one mode of delivery for bronchodilators over another during exacerbations of COPD with regard to these outcomes.
Overall completeness and applicability of evidence
The overall completeness of the evidence is low. Due to differences in outcome reporting we could not calculate the change in parameters from all studies. The evidence gathered related only to the comparison of nebulisers versus pMDIs. We found no studies investigating DPIs versus nebulisers using the same substance, nor studies with nebulised long-acting bronchodilators. Data about important clinical parameters, hospital readmission in 30 days, change in peak FEV 1 ′ and change in quality of life were not available. Participants in the included studies were all treated in a hospital setting rather than at home. Turner 1988 reported on an emergency department setting, from which most participants were not admitted. We recognise that the setting in which a patient receives treatment may have an impact on the choice of treatment mode, beyond concerns solely about the efficacy of the method. The paucity of data in this review has not allowed us to comment on the effect of the trial setting on the outcomes. We noticed a lack of standardised definitions in both COPD and exacerbations, which might influence the generalisability of the findings, although this lack of standardised definitions is also present in regular clinical practice. Thus, it is not entirely clear whether our results apply to all patients who present to a hospital with an exacerbation of COPD. Additional studies could prove useful in providing further evidence towards the difference we signalled in bronchodilator effects in favour of the nebuliser treatment. However, readers should keep in mind that the mean clinically important difference for the FEV 1 is generally reported to be 100 to 140 ml (Cazzola 2008; Jones 2014). Many practitioners commonly prescribe nebulisers for the acute exacerbation of COPD. Based on the results of our review, there is no evidence to either support or refute this practice. This might influence the applicability of the evidence; however, given the lack of evidence provided in this review, it is even more important to adequately assess the individual patient, the available modes of nebulisers and the available pMDIs and spacers. There are several important differences between different types of modern nebulisers, for instance regarding inhaled dose, delivered dose and the use of the compressor (De Boer 2003; Le Brun 1999) . In the absence of good quality evidence, such an assessment might provide guidance to select the optimal treatment for each patient.
Quality of the evidence
We used the GRADE assessment to qualify the amount of evidence of the outcomes, reporting this in the Summary of findings for the main comparison. Overall the quality of the evidence was low and sometimes even lacking. The studies that were included in this review are relatively small, and we downgraded the quality of the outcomes to reflect this. Especially for the primary outcome measuring FEV 1 at one hour, we could only include one older trial (Berry 1989). We therefore downgraded the evidence for this outcome. Heterogeneity varied across individual outcomes, ranging from I 2 = 0% to I 2 for = 47% for change in FEV 1 (ml) closest to one hour after dosing. The evidence was relatively old, with studies performed from at least 9 years and up to 31 years prior to this systematic review. This might influence the results, since modern nebulisers, pMDIs and DPIs may work in a different way than the ones used 30 years ago.
It is important to note the lack of standardised dose of bronchodilators between the different designs. Although actual lung deposition is generally held to be lower by nebuliser than by pMDI when using the same dose in both devices, good data are sparse. We noticed a significant variation in dose between the studies. Additionally, the type of nebuliser, compressor and pMDI used in trials will influence the actual lung deposition (De Boer 2003; Le Brun 1999; Mazhar 2007) . This might influence results, although it is unclear to what extent. We downgraded the quality of the evidence due to the combination of relatively old studies and dose variation.
Potential biases in the review process
A potential bias in our review process is publication bias. We found several studies reported only as abstracts. Although we tried, we could not retrieve a full data set from the study authors for several reasons. The data reported in the abstracts were not sufficient to allow recalculation for our outcomes, except in the case of the study by Moss 1985.
Agreements and disagreements with other studies or reviews
Although the data for the primary outcome did not show significant differences, this systemic review suggests for the first time that treatment with nebulisers during an exacerbation of COPD may improve FEV 1 more than pMDI with a spacer. However, it is very difficult to interpret this result correctly due to the previously discussed bias. We therefore concur with the earlier findings from Turner 1997 and Dolovich 2005. They did not find significant differences and concluded that there is not enough evidence to favour a mode of delivery for bronchodilators during exacerbations of COPD. Both reviews used asthma patients in their analysis, and both focused on FEV 1 or peak flow. A systematic review in mechanically ventilated patients with a need for aerosol bronchodilator therapy found no difference in bronchodilator effects, although they were only able to pool two studies with 28 participants in total for this outcome (Holland 2013).
A U T H O R S ' C O N C L U S I O N S Implications for practice
Due to inconclusive findings for our primary outcomes and all but one of our secondary outcomes, risk of bias, and relatively low numbers of studies and participants (eight studies involving 250 participants), the existing published data do not provide enough evidence to firmly favour one mode of delivery for bronchodilators over another during exacerbations of COPD. One secondary outcome suggests that treatment with nebulisers during an exacerbation of COPD slightly outperforms pMDI plus spacer with regard to improving FEV 1 ; however, this finding should be interpreted with care. Limited data about nebulisers versus pMDIs plus spacer are available. No data of sufficient quality have been published comparing nebulisers in this setting versus DPIs. We did not identify any studies of nebulised long-acting drugs. Most studies tested on one day only, in a cross-over design.
Implications for research
More studies are required to assess the optimal mode of delivery during exacerbations of COPD. In particular, data about DPIs versus nebulisers are lacking. There seems to be a larger effect on FEV 1 with the nebuliser. However, larger studies could shed more light on this and should take into account the considerable difference in the total administered dose between nebulisation and pMDI, and indeed the differences between different nebuliser designs and inhalers devices. The outcomes of these studies have traditionally focused at bronchodilating effects. Future studies should also assess different parameters such as adverse events, dyspnoea and quality of life. Patients, both in the acute setting and even in a stable state of COPD, seem to be more satisfied with nebulised administration than can be understood from the bronchodilatory data. Further research may be required to investigate the acceptability of different drug delivery modes in patients who may be accustomed to receiving nebulised treatment during an exacerbation. In times of strain on the medical system and its costs, length of stay and time to readmission would be valuable additional parameters for trials to consider. Investigators should report data about patients with COPD, asthma or an overlap syndrome separately. Future research evaluating nebuliser treatment compared with pMDI or DPI during COPD exacerbations should report findings as a change in means with standard error or standard deviation, or studies should provide sufficient data in the study report to enable calculation of these values. This will enable a metaanalysis of the study findings. We would also advise researchers to perform a power analysis when planning any new trials.The value of long-acting bronchodilators in the treatment of exacerbations, as well as their optimal modes of delivery, is totally unknown but would be valuable to study, especially since they have been shown to reduce hyperinflation and improve dyspnoea in stable state and are the standard of care after discharge (Van Geffen 2015a). 
A C K N O W L E D G E M E N T S
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Berry 1989
Methods
Cross Investigators did not report SDs or confidence intervals, and we could not reach them to obtain these. With help from our statistician, we calculated the SDs (assuming they were equal in both groups) The raw data provided us with a mean change in FEV 1 in litres of 0.12 (oral/pMDI group, N = 19) and 0.13 in the (IV/NEB group, N = 15) Based on the formula t = (y 1 − y 2 )/ (SD * √ (1/N 1 +1/N 2 )) t = 0.15 based on the P value provided by the article, y = change. Thiswould make y 1 = 0.12, y 2 = 0.13, N 1 = 19 and N 2 = 15; we calculated the SD to be 0.193. We used a similar calculation to calculate the SD for the Borg score. Here t was 0.41 based on the provided P value. SD was calculated to be 1.55. For length of stay t = 0.85 SD was calculated to be 2.73. 
Risk of bias
S O U R C E S O F S U P P O R T Internal sources
• The authors declare that no such funding was received for this systematic review, Other.
External sources
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
We published our planned strategy and methods earlier as a protocol (Van Geffen 2015b).
We updated the Background section to include the most recent literature.
We excluded RCTs involving asthma patients and mechanically ventilated patients due to the differences in patients, inhalation and airways in this setting. We did not describe this in our protocol because we did not expect these trials to turn up during our search. There are separate Cochrane reviews for these groups (Cates 2013; Holland 2013) .
As reported in the protocol, safety is an important outcome of the review; to clarify this, we added safety assessment as an objective to the review.
Initially, we aimed only to include full-text papers; however, based on both Cochrane policy and optimal data gathering, we decided to include abstracts in the review.
The included studies defined COPD in several different ways although we anticipated all studies to follow the American Thoracic Society (ATS) or Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. We reported the definition used by each study in the 'Characteristics of included studies' table, and we reported it specifically in our risk of bias tables if we considered that the definition introduced bias.
We initially formulated one of our secondary outcomes, 'Change in FEV 1 closest to one hour after dosing', as within six hours after dosing. However, one study did not report the time of their measurements (Shortall 2002), so we cannot claim with certainty that it happened within six hours after dosing. Nevertheless, one can assume based on their manuscript that the measurements actually were performed within six hours. For this reason we chose not to exclude this report for the meta-analysis.
Due to the cross-over design of the included trials, we used the GIV method to analyse outcomes 1.1, 2.2 and 2.3.
We had planned several subgroup analyses, but due to the small number of included studies, we were not able to provide a meaningful pooled analysis by mechanism (anticholinergic or beta-adrenergic), by short-acting versus long-acting agent, or to analyse subgroups
